TNFRSF9 and Hodgkins lymphoma: This bispecific antibody shows enhanced binding and antibody-dependent, cell-mediated cytotoxicity (ADCC) to CD30, CD137-double positive cells, which designates it as a promising candidate for a more efficacious and safer HL treatment.